R&D is driven forward by Creavis, our strategic innovation unit. Working closely with the segments, Creavis is engaged in research into new technologies.

Creavis concentrates on mid- and long-term innovation projects that support Evonik’s growth and sustainability strategy and provide access to new business options. In addition, it identifies future-oriented topics and acts as an internal incubator for Evonik. Work on innovation projects of a crossorganizational nature is organized in project houses. Experts from the organizational units involved in a project house normally work together for a period of three years on the project house’s development topics.Tissue Engineering, our twelfth project house, which was established at the R&D hub in Singapore in 2018, is working on new solutions to grow living cells. Its work supports the Healthcare Solutions innovation growth field.The aim is to produce materials for biological implants for medical applications. Research is currently being carried out into optimized approaches to skin models with better predictive power and sclability, plus excellent reproducibility for the Cosmetic Solutions innovation growth field. These approaches will be used in laboratory research and testing, for example, to test active ingredients for cosmetics, cleaning agents, and chemicals.

Evonik and Siemens have launched Rheticus II, a joint research project that aims to develop an efficient and powerful test facility to produce specialty chemicals with the aid of bacteria - using carbon dioxide (CO2), water and electricity from renewable sources. In the Rheticus I project, the two companies previously worked for two years to develop the technically feasible basis for this artificial photosynthesis process during a bioreactor and electrolyzer. Evonik and Siemens are now combining these two previously separate plants in a test facility at Evonik's site in Marl (Germany).

More information: